Fig. 10.

Therapeutic strategies targeting Notch signaling in human malignancies. Various pharmacological agents aimed at the Notch pathway have been developed, including γ-secretase inhibitors (GSIs), ADAM inhibitors, antibodies against Notch receptors or ligands, inhibitors targeting the Notch transcription complex, and γ-secretase modulators (GSMs). (Figure created with BioRender.com). DLL3 delta-like ligand 3, DLL4 delta-like ligand 4, ADAM a disintegrin and metalloprotease, NECD Notch extracellular domain, NICD Notch intracellular domain, Co-A coactivator, MAML mastermind-like, CSL CBF1/suppressor of hairless/Lag1